Outcomes of immunocompromised versus immunocompetent patients with SARS-Cov-2 infection depending on the therapy administered at the Respiratory Center of the University Hospital Center Osijek Objectives: The aim of this study was to determine the difference of the outcomes in immunocompromised patients verus immunocompetent control group depending on the administered therapy, demographic factors and comorbidities. Study Design: cross-sectional study with historical data Patients and Methods: The study included 103 COVID-19 positive patients, 58 (56 %) immunocompetent and 45 (44 %) immunocompromised, treated at the Respiratory Center of the University Hospital Center Osijek, in the period from April 2021. to April 2022. Data on age, sex, existing comorbidities, the length of hospitalization and the therapy administered during the hospitalization were collected from the available medical documentation. Results: The mortality of immunocompromised patients was 88,9 % in comparison to 67,2 % among the immunocompetent (Fischer's exact test, P = 0,01). There was no difference in the outcomes depending on the administered therapy of corticosteroids, remdesivir, reconvalescent plasma, immunoglobulins, or other biological medications. The median duration of hospitalization among the immunocompetent was 7 days versus 6,5 among the immunocompromised, and no difference in hospitalization length was found depending on the administered therapy. No differences of the outcomes of the immunosupressed versus immunocompetent depending on the sex, gender, or administered therapy were found. Conclusion: The study showed that the immunosuppressed patients have significantly worse outcomes compared to the immunocompetent control. Corticosteroids, remdesivir, reconvalescent plasma, immunoglobulins or other biological therapy had no effect on the outcomes of the immunosupressed patients opposed to the control group. Administered therapy showed no effect on the duration of the hospitalization of both groups. Age and sex of the patients, as well as existing hipertension or diabetes mellitus had no effect on the outcome of both immunosupressed and immunocompetent groups.